Noxafil — CareFirst (Caremark)
Oropharyngeal candidiasis (moderate to severe)
Preferred products
- fluconazole
- itraconazole oral solution
Initial criteria
- For oropharyngeal candidiasis: the request is for Noxafil oral suspension (immediate-release)
- For oropharyngeal candidiasis: patient has experienced an inadequate treatment response, intolerance, or has a contraindication to fluconazole AND itraconazole oral solution
- For prevention of invasive Aspergillus and Candida infections: requested drug is being prescribed for a patient who is at high risk of developing these infections due to being severely immunocompromised
- For treatment of invasive aspergillosis: requested drug is for Noxafil injection or Noxafil delayed-release tablets
Approval duration
Oropharyngeal candidiasis: 1 month; Prevention of invasive Aspergillus and Candida infections: 6 months; Treatment of invasive aspergillosis: 3 months